PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ( TSXV: CNVI ) (“ Conavi Medical ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospectus (the “ Preliminary... Read More

Mark Quick Appointed Chief Financial Officer, Bringing Extensive Public Company Capital Markets Expertise Current CFO, Stefano Picone, will take on a Transitional Strategic Role to Support Leadership Continuity During Growth Phase Leadership additions follow submission of next-generation Novasight™ to the FDA for 510(k) clearance TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical (“Conavi” or the “Company”), a... Read More

Agreement to provide up to $2.5 million CAD to Conavi Medical to support the commercial launch of the next-generation Novasight Hybrid system TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular... Read More

Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technology TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a commercial-stage medical device company focused on intravascular imaging solutions, today announced that it will participate in the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, taking place October 25 –... Read More

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it will be presenting at the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub on Wednesday,... Read More

US FDA 510(k) Submission Follows the Successful Validation Testing with KOLs FDA 510(k) Clearance Anticipated During H1 2026 and Company Preparing for US Commercial Launch following Clearance Coronary Intravascular Imaging Market Expected to Grow to over $1 bil USD by 2028 TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical... Read More

US FDA 510(k) submission remains on track for calendar Q3 2025 Successful validation testing of Novasight Hybrid™ system with key opinion leaders Recent academic publications underscore importance of intravascular imaging and potential of hybrid IVUS / OCT $20 million financing completed in April strengthens balance sheet and supports anticipated U.S. launch TORONTO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp.... Read More

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intravascular imaging, is pleased to announce the publication of a compelling case report in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlighting the clinical impact of the Company’s Novasight™ Hybrid IVUS-OCT System in guiding accurate diagnosis and optimal stent placement... Read More

TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intracoronary imaging technologies, is pleased to highlight the recent publication in The American Journal of Cardiology titled “Regional Disparities and Predictors of Intracoronary Imaging Use During Percutaneous Coronary Intervention in the United States”. This comprehensive analysis, based on over 1.8 million... Read More

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), is pleased to invite investors and other interested parties to attend the Company’s upcoming live webinar presentation, audience Q&A and interview. CEO Tom Looby will discuss Conavi's unique and market-leading imaging technology for minimally invasive cardiovascular procedures. The webinar will be... Read More

TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“ Conavi Medical ” or the “ Company ”), announced that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) Plan on June 2, 2025 pursuant to the terms of its Omnibus Equity Incentive Plan. A total of 5,849,098 Stock Options have been awarded to directors, officers, employees and consultants... Read More

New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight’s unique value proposition Upsized $20 million financing led by U.S. institutional investors is expected to fund key value inflection points through planned commercial launch of next-generation Novasight Hybrid™ System in H1 2026 U.S. FDA 510(k) submission remains on track for... Read More

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”) , a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Novasight Hybrid™ System (“Novasight”) has been named "Product Innovation of the Year" at the 2025 Minnesota... Read More

Toronto, Ontario--(Newsfile Corp. - April 25, 2025) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (" Conavi " or the " Company "), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO of Conavi Medical, will present and participate in one-on-one meetings at the... Read More

TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has closed its previously announced, upsized equity offering for aggregate gross proceeds of $20... Read More

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering. The offering is of common shares of the... Read More

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp . (TSXV: CNVI; OTCQB: CNVIF) (“ Conavi Medical ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today the results of its annual general meeting of shareholders held virtually on March 31, 2025 (the... Read More

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to provide an update in respect of its previously announced public offering (the “ Offering ”). The Company expects... Read More

E xpected to enhance visibility and access to U.S. investors Trading to commence on March 6, 2025 TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“ Conavi Medical ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that... Read More

IVUS and OCT cited as playing essential and complementary roles, validating Novasight’s unique hybrid imaging capability Guidelines constitute strong recommendations based on the highest level of evidence Clinical data show intracoronary imaging leads to lower risk of target vessel failure (including cardiac death) in coronary procedures Company anticipates similar changes to other guidelines covering coronary procedures... Read More

Completed first quarter as a public company and raised $10.6 mil CAD concurrent with listing Next-generation Novasight design freeze completed on schedule, usability testing and system validation expected to complete next quarter U.S. FDA submission on track for Q3 calendar 2025 TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi Medical ” or the “ Company ”), a commercial stage medical... Read More

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi ” or the “ Corporation ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedure, is pleased to announce that it has entered into a Corporate Development and Strategic services agreement with BND Projects Inc. (“ BND ”).... Read More

TORONTO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi Medical ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedure, announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in the... Read More

U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026 Evolving medical guidelines position next-generation Novasight system as new imaging standard in interventional cardiology Multiple non-dilutive opportunities being pursued to fund growth TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) -- To our Shareholders, As we enter 2025, I’m encouraged by our... Read More

TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi Medical ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the publication of a detailed review of its collaboration with U.S.-based Minnetronix, a world... Read More

Completed US$7.7 million financing and reverse takeover to take Company public Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp . (TSXV: CNVI) (“ Conavi Medical ” or the “... Read More

Marks first time as a public company that Conavi is presenting at an investor event Live webcast presentation on Wednesday, December 11ᵗʰ at 3:35 p.m. ET TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi Medical ” or the “ Company ”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular... Read More

Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to EOM Conavi Medical eligible to receive future tiered royalty payments, ranging from 5.0%-10.0%, on net EOM coronary imaging system sales in China TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi Medical ” or the “ Company ”), a... Read More

Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries Company showcasing its Novasight technology this week at TCT 2024 TORONTO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi Medical ”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies... Read More

TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- CONAVI MEDICAL CORP. (TSXV: CNVI) (“ CONAVI MEDICAL ” or the “ Company ”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has engaged the services of ICP Securities Inc. (“ ICP ”) to provide automated market making services, including use... Read More